130 related articles for article (PubMed ID: 3458337)
1. Oral idarubicin in adult acute leukemia: a preliminary experience.
Lambertenghi-Deliliers G; Pogliani E; Annaloro C; Pacciarini MA; Polli EE
Tumori; 1986 Apr; 72(2):157-61. PubMed ID: 3458337
[TBL] [Abstract][Full Text] [Related]
2. Preliminary observations on intravenous idarubicin (4-demethoxydaunorubicin) in the chronic and accelerated phase of chronic myelogenous leukemia.
Battista R; D'Emilio A; Vespignani M; Pacciarini MA; Dini E
Tumori; 1986 Aug; 72(4):389-93. PubMed ID: 3464125
[TBL] [Abstract][Full Text] [Related]
3. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.
Ganzina F; Pacciarini MA; Di Pietro N
Invest New Drugs; 1986; 4(1):85-105. PubMed ID: 3516918
[TBL] [Abstract][Full Text] [Related]
4. Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia.
Lambertenghi-Deliliers G; Maiolo AT; Annaloro C; Cortelezzi A; Pogliani E; Ganzina F; Polli EE
Eur J Cancer Clin Oncol; 1987 Jul; 23(7):1041-5. PubMed ID: 3478198
[TBL] [Abstract][Full Text] [Related]
5. Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.
Seddon AN; Chaim J; Akin O; Drill E; Michael AG; Adel N; Tallman MS
Leuk Res; 2018 May; 68():48-50. PubMed ID: 29544131
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic activity of 4-demethoxydauno-rubicin (idarubicin) in adult acute leukemia.
Lambertenghi-Deliliers G; Pogliani E; Maiolo AT; Pacciarini MA; Polli EE
Tumori; 1983 Dec; 69(6):515-9. PubMed ID: 6582678
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia.
Pui CH; de Graaf SS; Dow LW; Rodman JH; Evans WE; Alpert BS; Murphy SB
Cancer Res; 1988 Sep; 48(18):5348-52. PubMed ID: 3165708
[TBL] [Abstract][Full Text] [Related]
8. Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia.
Daghestani AN; Arlin ZA; Leyland-Jones B; Gee TS; Kempin SJ; Mertelsmann R; Budman D; Schulman P; Baratz R; Williams L
Cancer Res; 1985 Mar; 45(3):1408-12. PubMed ID: 3855696
[TBL] [Abstract][Full Text] [Related]
9. [A phase I trial of idarubicin by oral administration].
Ogawa M; Kimura K; Taguchi T; Wakui A; Hattori M; Shimoyama T; Fujita H
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1896-900. PubMed ID: 3473981
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of oral idarubicin in metastatic melanoma.
Martoni A; Pacciarini MA; Piana E; Pannuti F
Chemioterapia; 1986 Dec; 5(6):414-5. PubMed ID: 3467876
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
Tamura K
Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia.
Hayat M; Hurteloup P; Parmentier C; Carde P; Pico JO; Schlumberger M; Chahine G; Kamioner D
Invest New Drugs; 1984; 2(4):375-9. PubMed ID: 6595242
[TBL] [Abstract][Full Text] [Related]
13. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.
Robert J; Rigal-Huguet F; Harousseau JL; Pris J; Huet S; Reiffers J; Hurteloup P; Tamassia V
Leuk Res; 1987; 11(11):961-4. PubMed ID: 3480399
[TBL] [Abstract][Full Text] [Related]
15. Oral idarubicin in non-Hodgkin's lymphomas.
Lopez M; Di Lauro L; Papaldo P
Invest New Drugs; 1986; 4(3):263-7. PubMed ID: 3469170
[TBL] [Abstract][Full Text] [Related]
16. Idarubicin in refractory acute leukemia.
Fülle HH; Hellriegel KP
Onkologie; 1986 Jun; 9(3):152-3. PubMed ID: 3528962
[TBL] [Abstract][Full Text] [Related]
17. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
Creutzig U; Zimmermann M; Bourquin JP; Dworzak MN; Fleischhack G; Graf N; Klingebiel T; Kremens B; Lehrnbecher T; von Neuhoff C; Ritter J; Sander A; Schrauder A; von Stackelberg A; Starý J; Reinhardt D
Blood; 2013 Jul; 122(1):37-43. PubMed ID: 23704089
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
Chisesi T; Capnist G; de Dominicis E; Dini E
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):681-4. PubMed ID: 3164269
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of idarubicin administered i.v. to pediatric patients with acute lymphoblastic leukemia.
Madon E; Grazia G; De Bernardi B; Comelli A; Carli M; Sainati L; Paolucci G; Canino R; Colella R; Bagnulo S
Cancer Treat Rep; 1987 Sep; 71(9):855-6. PubMed ID: 3476202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
